Approval · Notice of Compliance 17162 · 2015
TEVA-DIVALPROEX: Notice of Compliance 17162
Issued August 4, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17162
- Date
- August 4, 2015
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change
- Therapeutic class
- Antiepileptic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-DIVALPROEX | 02239701 | Cancelled Post Market |
| TEVA-DIVALPROEX | 02239702 | Cancelled Post Market |
| TEVA-DIVALPROEX | 02239703 | Cancelled Post Market |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB